ADC
-
【Product for Licensing】A Highly Differentiated EGFR x HER2 Bispecific ADC for Targeted Therapy of Multiple Types of Solid Tumors
If you are interested in this candidate, please contact DrugTimes BD Team at BD@drugtimes.cn
-
【Product for Licensing】A Highly Differentiated B7-H3 x PSMA Bispecific ADC, Potentially Best-in-Class, for the Treatment of mCRPC
If you are interested in this candidate, please contact DrugTimes BD Team at BD@drugtimes.cn
-
Merck Halts Two Phase III Clinical Trials
Drug development is not easy, and we pay tribute to the heroes of innovative drug development!
-
当ADC叩响 “痴呆症” 的大门
2024年7月28日-8月1日，阿尔茨海默病协会国际会议（AAIC）在费城成功举办。会议上，来自世界各地的专业研究人员和临床医生就阿尔茨海默病（AD）的防治分享了各自精彩见解。 在…
-
美国上市公司寻找创新性ADC、双抗，您感兴趣吗？| 药时代BD项目
如果贵公司对这个机会感兴趣，请速速联系药时代BD团队！
-
American listed companies are looking for innovative ADCs and bispecific antibodies. Are you interested in this opportunity? | DrugTimes BD Project
Please contact the DrugTimes BD team as soon as possible!
-
诺和、礼来看好的ADC payload，您感兴趣吗？| 药时代BD项目
如果贵公司对新型NMTi payload感兴趣，请速速联系药时代BD团队！
-
Novo and Eli Lilly’s favored ADC payload, are you interested? | DrugTimes BD Project
If your company is interested in the new NMTi payload, please contact DrugTimes BD team as soon as possible!
-
8 Key Highlights! What Do Global Pharma Industry BD and M&A Trends Forecast for 2024?
Where Pharma is Investing for the Future of Medicine: Biopharma Deal Making in 2024
-
Gilead | A Ray of Hope for the Highly Anticipated TROP2 ADC Trodelvy
DrugTimes team will follow up on this hot field and report timely. Please stay tuned. Many thanks!~
